Ferijet 500mg IV Injection or Infusion 10ml vial

Ferijet injection is indicated for the treatment of iron deficiency anemia in adult patients:

• who have intolerance to oral iron or have had an unsatisfactory response to oral iron.
• who have non-dialysis-dependent chronic kidney disease.

The posology of Ferric Carboxymaltose follows a stepwise approach: 

1. determination of the individual iron need
2. calculation and administration of the iron dose(s)
3. post-iron repletion assessments.

Step 1: Determination of the iron need: The individual iron need for repletion using Fematos is determined based on the patient's body weight and haemoglobin (Hb) level. The following list for determination of the iron need:

Hb <10 g/dl

• Below 35 kg: 500 mg
• 35 kg to <70 kg: 1500 mg
• 70 kg and over: 2000 mg

Hb 10 to 14 g/dl

• below 35 kg: 500 mg
• 35 kg to <70 kg: 1000 mg
• 70 kg and over: 1500 mg

Hb >14 g/dl

• Below 35 kg: 500 mg
• 35 kg to <70 kg: 500 mg
• 70 kg and over: 500 mg

Step 2: Calculation and administration of the maximum individual iron dose(s): Based on the iron need determined above, the appropriate dose(s) of Ferric Carboxymaltose should be administered, taking into consideration the following:

A single Ferric Carboxymaltose administration should not exceed:
 

• 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)
• 1,000 mg of iron (20 mL Ferric Carboxymaltose)
• The maximum recommended cumulative dose of Ferric Carboxymaltose is 1000 mg of iron per week.

Step 3: Post-iron repletion assessments: Re-assessment should be performed by the clinician based on the individual patient's condition. The Hb level should be re-assessed no earlier than 4 weeks post final Ferric Carboxymaltose administration to allow adequate time for erythropoiesis and iron utilisation. In the event the patient requires further iron repletion, the iron need should be recalculated using the above list.

The use of Ferric Carboxymaltose is contraindicated in cases of:
 

• hypersensitivity to the active substance, to Ferric Carboxymaltose or any of its excipients
• known serious hypersensitivity to other parenteral iron products
• anaemia not attributed to iron deficiency, e.g. other microcytic anaemia
• evidence of iron overload or disturbances in the utilisation of iron

The side effects of Ferijet are infrequent, usually mild & generally do not cause patients to stop treatment.

The most common side effect: nausea, followed by headache, dizziness, and hypertension, injection site reactions, nausea, alanine aminotransferase increased, hypophosphataemia.

Uncommon side effects: hypersensitivity, dysgeusia, tachycardia, hypotension, flushing, dyspnoea, dyspepsia, abdominal pain, constipation, diarrhea, Pruritus, urticaria, erythema, rash, myalgia, back pain, arthralgia, muscle spasms, Pyrexia, fatigue, chest pain, oedema peripheral, chills, aspartate aminotransferase increased, gamma glutamyl transferase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased.

Rare side effects: anaphylactoid reactions, loss of consciousness, anxiety, phlebitis, syncope, presyncope, bronchospasm, flatulence, angioedema, pallor, and face oedema, rigors, malaise, influenza-like illness.

There are no adequate and well-controlled trials of Ferric Carboxymaltose in pregnant women. A careful benefit/risk evaluation is required before use during pregnancy, and Ferric Carboxymaltose should not be used during pregnancy unless clearly necessary. Animal data suggest that iron released from Ferric
Carboxymaltose can cross the placental barrier and that its use during pregnancy may influence skeletal development in the fetus. Treatment with Ferric Carboxymaltose should be confined to the second and third trimester if the benefit is judged to outweigh the potential risk for both the mother and the fetus. Based on limited data on breast-feeding women, it is unlikely that Ferric Carboxymaltose represents a risk to the breast-fed child.

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferijet. Patients may present with shock, clinically significant hypotension, loss of consciousness, and collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferijet administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferijet when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which include, but are not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.

Hypertension: Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea, may occur. These elevations generally occur immediately after dosing and resolve within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferijet administration.

Laboratory Test Alterations: In the 24 hours following administration of Ferijet, laboratory assays may overestimate serum iron and transferrin-bound iron by also measuring the iron in Ferijet.

Patients with haemodialysis-dependent chronic kidney disease: A single maximum daily injection dose of 200 mg iron should not be exceeded in haemodialysis-dependent chronic kidney disease patients.

Paediatric population: The use of Ferijet has not been studied in children, and therefore is not recommended in children under 14 years.

Store in a cool (below 30°C) & dry place, away from light. Do not freeze. Keep out of the reach of children.